For protecting human health
We focus on the R&D of new drugs to solve unmet clinical needs
Shenzhen Sungening Biological Co., Ltd is a R&D-driven global innovative biopharmaceutical company focusing on the field of metabolic diseases, anti-tumor and anti-infection diseases in which high unmet clinical needs were identified.
Our mission is to solve the clinical needs for new drug R&D and protect human health and safety. Based on rich experience in innovation and powerful entrepreneurial team, with the introduction of the world’s top biological and pharmaceutical experts, oriented with the world’s latest MOA research achievements, we strive to develop multiple classic drugs to solve clinical needs, to become a great company laying emphasis on values, methods and results, to have profound significance to the world.
Dr. Chenguang Yuan, Co-founder, Senior Vice President and Chief Scientist officer (CSO)
Dr. Yuan is a pharmaceutical chemistry expert, graduated from Xiamen University and Colorado State University with bachelor and doctoral degree respectively, a distinguished expert of Sichuan Province, a high-level innovative talent of Fujian Province “100 Talents Plan”, a leading entrepreneurial talent of Xiamen “Double Hundred Talents Plan”, and an adjunct professor of the Academy of Biology of Xiamen University.
As former assistant researcher of Chengdu institute of organic chemistry, the Chinese Academy of Sciences, director researcher of Amgen company , senior vice President of Chengdu Hyperway Pharmaceuticals, Dr. Yuan has more than 30 years of innovative drug discovery experience, is good at innovative drug design and development, especially in first-in-class small molecular targeted anticancer drugs. He has a unique and keen insight in organic chemistry and drug synthesis, is the inventor of multiple innovative drug compounds. He has published 28 papers in well-known journals domestic and overseas, and has obtained 25 American compound invention patents.
Dr. Yan Chen, Co-founder, Senior Vice President and Chief Technology Officer (CTO)
Dr. Chen graduated from the Department of Medicine and Molecular Genetics of Indiana University, and is a tenured professor of Indiana University. He served as the director of the State Key Laboratory of Nutrition, Metabolism and Food Safety of Chinese Academy of Sciences, the vice president of Shanghai Institute of Chinese Academy of Sciences, and the director of Shanghai Institute of Nutrition of Chinese Academy of Sciences. He has been engaged in the basic research in the field of tumor and glucose and lipid metabolism for a long time. In recent years, he mainly focuses on the nutritional intervention of diabetes and other metabolic diseases. He is a well-known expert in the field of glucose and lipid metabolism research in China.
Dr. Chen is an outstanding young men winner of the State Foundation of China and enjoys the special government allowance of the State Council. He is selected as the national candidate of “New Century Millions Talent Project”, Academy of CAS. He is an excellent academic leader in Shanghai, won the “Meiji Dairy Science Award” and the “Tan Jiazhen Life Science Award”. He has also been funded by the American Cancer Society Postdoctoral Fund, the American Endocrinology Association Fund, the American Heart Association Scientists Development Fund and many other funds. He has been awarded the national Sino-American Biological co-cultured CUSBEA project. Published over 150 SCI academic papers, Posted in Nature, EMBO J, PNAS, Nat Communic, Mol Cell, Autophagy, Hepatology, Diabetes, Endocrinology, Cancer Research, Oncogene, and other journals. These papers were cited more than 4,000 times.